elicio.com (ELTX): Price/Earnings to Growth Ratio

Corporate company logo of Elicio Therapeutics, Inc (ELTX)

The lack of profit due to early-stage testing creates financial risks, as confirmed by the adjusted PEG ratio, where 0.00 represents the current metric. Elicio Therapeutics (ELTX) is scaling its Amphiphile platform for expansion into the oncology sphere, leveraging physician confidence in the AMPLIFY system and a positive brand image among investors.

ELTX Elicio Price/Earnings to Growth Ratio (02/21/2024 - 11/14/2026)

Analytical breakdowns for Elicio Therapeutics, Inc. (ELTX)

- share price and consensus valuation forecast:
Price Performance Chart Elicio Therapeutics, Inc|ELTX - Price Target Chart
- stock exchange capitalization data:
Market Value Elicio Therapeutics, Inc.|ELTX - Real Price to Acquire Entire Company
- issuer book value statistics:
Net Asset Value per Share Elicio Therapeutics|ELTX - Company Book Value|Market Cap to Net Assets Ratio elicio.com|ELTX - Aggregate Company Assets
- business debt structure and liquidity details:
Aggregate Debt to Equity Elicio Therapeutics|ELTX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Elicio Therapeutics Inc.|ELTX - Company Debts|Debts to Book Value Elicio Therapeutics|ELTX - Company Long-Term Debt|Company Short-Term Indebtedness Elicio Therapeutics|Immediate Liquidity elicio.com
- earnings and multiples data:
ELTX - Net Profit|Net Profit Forecast Elicio Therapeutics|ELTX - P/E Multiple|Projected Price to Earnings Ratio elicio.com|ELTX - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Elicio Therapeutics, Inc|ELTX - Operating profit EBITDA|Net earnings per one share for the last twelve months Elicio Therapeutics|ELTX - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months elicio.com|ELTX - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Elicio Therapeutics
- total revenue and sales volume data:
ELTX - Revenue and Sales Volume|Company Future Sales Volume Elicio|ELTX - P/S Multiple|Market Cap to Expected Sales Ratio Elicio Therapeutics
Fundamental company analysis:ELTX - Elicio Therapeutics, Inc
Flagship merchandise of elicio.com

The PEG ratio compares an asset's market value with its earnings growth, making it possible to identify company undervaluation when growth rates exceed one. An analysis of the peg_co metric confirms the operational resilience of Elicio Therapeutics (ELTX), as the absence of geopolitical risks in the US oncology sector makes the calculated business expansion rates more predictable and fundamentally sound for the investor.

Competitors of Elicio Therapeutics

CRVS (Corvus Corp) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Prelude PRLD